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Abstract
The incidence of many common cancers varies between different populations and 
appears to be affected by a Western lifestyle. Highly proliferative malignant cells require 
sufficient levels of nutrients for their anabolic activity. Therefore, targeting genes and 
pathways involved in metabolic pathways could yield future therapeutics. A common 
pathway implicated in energetic and nutritional requirements of a cell is the LKB1/AMPK 
pathway. Metformin is a widely studied anti-diabetic drug, which improves glycaemia 
in patients with type 2 diabetes by targeting this pathway. We investigated the effect 
of metformin on prostate cancer cell lines and evaluated its mechanism of action using 
DU145, LNCaP, PC3 and VCaP prostate cancer cell lines. Trypan blue dye-exclusion assay 
was used to assess levels of cell death. Western immunoblotting was used to determine 
the abundance of proteins. Insulin-like growth factor-binding protein-2 (IGFBP-2) and 
AMPK genes were silenced using siRNA. Effects on cell morphology were visualised 
using microscopy. IGFBP-2 gene expression was assessed using real-time RT-PCR. With 
DU145 and LNCaP cells metformin alone induced cell death, but this was reduced in 
hyperglycaemic conditions. Hyperglycaemia also reduced the sensitivity to Docetaxel, but 
this was countered by co-treatment with metformin. LKB1 was required for the activation 
of AMPK but was not essential to mediate the induction of cell death. An alternative 
pathway by which metformin exerted its action was through downregulation of IGFBP-2 
in DU145 and LNCaP cells, independently of AMPK. This finding could have important 
implications in relation to therapeutic strategies in prostate cancer patients presenting 
with diabetes.
Introduction
Prostate cancer (PCa) is the most common non-cutaneous 
cancer in men, and it accounts for the second highest 
cause of mortality among men in the US after lung cancer 
(Siegel et al. 2012).
The global obesity and associated diabetes epidemics 
have been linked with an increase in the development 
and/or progression of a number of cancers. In general, 
epidemiology has revealed an inverse correlation 
Open Access
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between diabetes and risk of developing PCa considered 
to potentially be due to the insulin resistance occurring 
in diabetes being accompanied by reduced levels of 
testosterone that is one of the main drivers for PCa 
progression. Men with diabetes are however at a 
greater risk of mortality from prostate cancer (Bonovas 
et  al. 2004, Kasper & Giovannucci 2006). Therefore, 
new ways are needed to improve response to current 
treatment and to decrease mortality associated with 
diabetes and PCa. There is currently a lot of interest 
in metformin, a drug commonly used to treat diabetes 
mellitus, that became a standard treatment after other 
members of the biguanides family, phenformin and 
buformin, which were discontinued due to increased 
risk of lactic acidosis (Kolata 1979, Bailey & Turner 
1996, Witters 2001).
Beneficial effects of metformin have been described 
with an apparent decrease in the incidence of several 
cancers. Patients with diabetes had a significantly lower 
risk of developing colon cancer with metformin use 
(Tseng 2012). Metformin use has also been associated 
with reduced prevalence of breast (Libby et al. 2009) and 
pancreatic cancers (Currie et al. 2009). Studies of men with 
localised prostate cancer showed that the use of metformin 
was associated with an improvement in cancer-specific 
survival and a decrease in the transition from androgen-
sensitive to castration-resistant PCa (CRPC) (Spratt et al. 
2013). Other studies have also suggested a beneficial effect 
of metformin use in patients with diabetes in relation to 
cancer incidence (Murtola et al. 2008, Wright & Stanford 
2009) and improved survival in prostate cancer patients 
(He et al. 2011).
The anticancer effects of metformin could be 
mediated by a canonical pathway involving the activation 
of AMP-activated protein kinase (AMPK). In response 
to low energy levels or cellular stress, a conformational 
change is induced in the AMPKγ regulatory subunit that 
results in the exposure of the AMPKα catalytic subunit 
to phosphorylation of threonine residue (Thr-172) 
by liver kinase B1 (LKB1/STK11) (Shackelford & Shaw 
2009). Activated AMPK can then control cell growth and 
proliferation by regulating the activity of the mammalian 
target of rapamycin (mTOR) (Wullschleger et  al. 2006). 
This results in an inhibition of protein synthesis and 
proliferation. Whether the presence of LKB1 is required 
for the actions of metformin are however not clear. In 
some studies, metformin was unable to inhibit cell growth 
in LKB1-negative HeLa cells but did reduce growth in 
LKB1-positive breast cancer (MCF7) and normal breast 
epithelial cells (MCF10a) or in prostate cancer cells (PC3) 
(Zakikhani  et  al. 2006). In contrast to this study, Algire 
and coworkers showed that metformin was able to reduce 
tumour growth induced by a high-fat diet and high glucose 
regardless of LKB1 expression in vivo (Algire et al. 2011).
In our study, we present data showing that metformin 
can act in an LKB1-AMPK-independent way to induce 
prostate cancer cell death and counter hyperglycaemia-
induced chemoresistance and that these effects involve 
the regulation of IGFBP-2.
Materials and methods
Reagents
All chemicals, unless otherwise stated, were purchased 
from Sigma. Compound C was purchased from 
Millipore. All siRNAs were purchased from Qiagen and 
the transfection reagent (SR-1003-04) from Synvolux 
Therapeutics (Groningen, The Netherlands). Foetal 
bovine serum (FBS) was purchased from Invitrogen, 
DMEM-25 mM glucose (BF-709) and DMEM-5 mM glucose 
(BF-708), RPMI-1640, penicillin–streptomycin solution 
and l-glutamine were bought from Lonza (Basel, 
Switzerland). Human, recombinant non-glycosylated 
IGFBP-2 was obtained from GroPep (Thebarton, Australia).
Cell culture and imaging
Prostate cancer cell lines: androgen-independent DU145, 
PC3 and androgen-dependent LNCaP and VCaP were 
purchased from ATCC. DU145, PC3 and VCaP cells were 
grown in DMEM growth media supplemented with 10% 
v/v foetal bovine serum (FBS), penicillin–streptomycin 
(50 IU/mL) and 1% v/v l-glutamine solution (2 mM), and 
LNCaP cells were cultured in RPMI-1640 growth media 
supplemented with 10% v/v FBS and antibiotics. Cells 
were maintained in a humidified 5% carbon dioxide 
atmosphere at 37°C. For all experiments, cell lines were 
seeded in 5 mM glucose growth media (GM) for 24 h and 
next transferred to serum-free media (SFM) containing 
either 5 mM or 25 mM glucose, supplemented with 
sodium bicarbonate (1 mg/mL), bovine serum albumin 
(0.2 mg/mL) and transferrin (0.01 mg/mL). After a further 
24 h, the cells were dosed with Docetaxel (0–60 nM), 
Metformin (0–10 mM) and Compound C (2 µM) 
according to the respective figure legends. Dead cells 
were assessed using trypan blue cell counting as described 
previously (Thomas et al. 2010). Images were taken with a 
10× objective on Zeiss Axiovert microscope using Moticam 
5.0 MP camera (Hong Kong, China).
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Silencing AMPKα and IGFBP-2 using siRNA technology
Cells were seeded in 24-well or 6-well plates with cell a 
density of 0.04 × 106 cells/well and 0.3 × 106 cells/well 
respectively, in 5 mM glucose GM in the presence 
or absence of AMPKα1 siRNA (target sequence 
5′-CCGAAGTCAGAGCAAACCGTA-3′), AMPKα2 siRNA 
(target sequence 5′-CCCACGATATTCTGTACACAA-3′) 
and IGFBP-2 siRNA (target sequence CCCGGAGCA 
GGTTGCAGACAA) at a concentration of 75 nM for 
AMPK and 25 nM for IGFBP-2 or with a random sequence 
negative control siRNA (NSsiRNA). The next day GM 
was switched to SFM for a further 24 h before dosing 
with drugs of interest for another 24 h. Cell death 
was assessed as described in Thomas et  al. (2010), and 
IGFBP-2 and AMPK abundance were monitored using 
Western immunoblotting.
Western immunoblotting
Equal amount of protein lysates estimated by BCA protein 
assay (Thermo Fisher Scientific, 23225) or equal volume 
of concentrated cell conditioned media were separated 
on a 8–12% SDS-PAGE gels and transferred to Hybond 
N+ nitrocellulose membranes (Amersham, RPN119B). 
Non-specific binding sites on the membranes were 
blocked for a minimum of 2 h with 5% w/v milk or 3% 
w/v bovine serum albumin (BSA) for non-phosphorylated 
and phosphorylated proteins respectively in Tris-buffered 
saline (TBS)/2% v/v Tween (TBS/T) before overnight (4°C) 
probing with antiserum against phospho-AMPKα (Thr172) 
(1:1000: Cell Signalling 2535), LKB1 (1:1000 Santa 
Cruz sc-32245), IGFBP-2 (1:1000: Santa Cruz sc-6001), 
GAPDH (1:5000 Millipore MAB 374), tubulin (1:5000: 
Thermo Fisher Scientific, MZ05829) or β-actin (1:10,000 
Sigma-Aldrich A5441). Secondary anti-goat antibody 
was used at 1:2000 dilutions for IGFBP-2, anti-rabbit 
for Phospho-AMPKα at 1:2000 dilution or anti-mouse 
antibody (1:5000) for LKB1, tubulin, β-actin or GAPDH. 
Peroxidase binding was visualised by enhanced 
chemiluminescence and detected using ChemiDoc XRS+ 
System and analysed using Image Lab Software (BioRad, 
170-8265). Western immunoblots were quantified using 
BioRad Quantity One 4.6.5 1-D Analysis Software.
Quantitative RT PCR
Total RNA from cells seeded at 1 × 106 cells and cultured in 
T25 flasks were extracted using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. 2 μg of 
total RNA was used for cDNA synthesis with random 
hexamers. Real-time PCR was carried out using Green 
JumpStart SYBR (Sigma, H5041) and an ABI StepOne Plus 
Realtime PCR System (Applied Biosystems, 4376600). 
Reactions were run in duplicate in three independent 
experiments. Expression data were normalised to the 
geometric mean of a housekeeping gene (18S) to control 
the variability in expression levels and were analysed 
using the 2−∆∆CT method. PCR primers were designed 
using OligoPerfect online software from Qiagen under 
consideration of the special design criteria for real-time 
RT-PCR primers, spanning the junction between exons. 
IGFBP-2 primers for PCR were used with the following 
sequences: forward 5′-CCTCAAGTCGGGTATGAAGG-3′ 
and reverse 5′-ACCTGGTCCAGTTCCTGTTG-3′ 
(primer size 162 bp). 18S primers with the following 
sequences were used for normalization: forward 
5′-GATGTAGTTGCTTGGGACCCA-3′ and reverse 
5′-TGGAGATAACACTCTAAGCATAACTAAAGGT-3 ′ 
(primer size 140 bp) (both purchased from Thermo 
Scientific). Melt curves were performed for each RT-PCR 
analysis to ensure that no non-specific amplification was 
occurring (data not shown).
Statistical analysis
Data were analysed with SPSS 13.0 for Windows using 
one-way ANOVA followed by least significant difference 
(LSD) post hoc test. A statistically significant difference was 
considered to be present at P < 0.05.
Results
Effects of metformin on cell death of PCa cells
The effect of metformin (1–10 mM) was examined in 
DU145, LNCaP, PC3 and VCaP PCa cells cultured in either 
euglycaemic (5 mM) or hyperglycaemic (25 mM) conditions 
(Fig. 1). With DU145, we found that metformin was able 
to induce a dose-dependent increase in cell death under 
euglycaemic conditions compared with hyperglycaemic 
conditions where cell death was not significantly affected 
by any dose of metformin. A statistically significant 
difference between glucose conditions was observed 
at 5 mM metformin: cell death was only increased by 
4.2% (1.8-fold) in high glucose, compared with a 22.8% 
(4.8-fold) increase under euglycaemic conditions 
(Fig. 1A). A similar effect of metformin was seen in LNCaP 
cells, where we also observed an inability of metformin 
to induce cell death under hyperglycaemic conditions, 
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whereas a dose-dependent increase in cell death could 
be seen under euglycaemic conditions. A 5 mM dose of 
metformin was able to induce a 20% (2.6 fold) increase 
of cell death in 5 mM glucose, compared with a 5.5% 
(1.4-fold) increase in hyperglycaemic conditions (Fig. 1B).
In contrast to the increased cell death observed in 
response to metformin treatment under euglycaemic 
conditions with DU145 and LNCaP cells, we found a 
moderate effect on cell death in PC3 and VCaP cells in 
response to metformin under either normal or high levels 
of glucose (Fig.  1C, D). Differences in the response to 
metformin in normal or high glucose conditions were 
observed at a dose of 5 mM with DU145 and LNCaP cells, 
but no significant differences in response to metformin 
were observed in either PC3 or VCaP cells.
Figure  2A shows that treatment with metformin 
(2.5–7.5 mM) induced a significant reduction in DU145 
cell number with cells becoming rounded and detached 
from the surface of the culture dish when cultured 
in 5 mM glucose conditions, but no such effect was 
observed in 25 mM glucose media. LNCaP cells responded 
similarly to increased concentrations of metformin, and 
a dose-dependent reduction in cell growth in normal 
glucose conditions was observed but not in high glucose-
containing media (Fig. 2B). With VCaP cells, this pattern 
was observed only in the presence of 7.5 mM metformin 
in 5 mM glucose but not in 25 mM glucose (Fig. 2C). With 
PC3 cells, no differences in morphology were observed 
consistent with no effect of metformin on the induction 
of cell death (Fig. 2D).
We have published previously that hyperglycaemia 
confers survival against Docetaxel-induced cell death in 
DU145 and LNCaP but not PC3 PCa cell lines (Biernacka 
et  al. 2013). Epidemiology studies have reported that 
patients taking metformin have decreased cancer 
incidence and/or improved cancer prognosis (Murtola 
et  al. 2008, Wright & Stanford 2009, He et  al. 2011). 
We then assessed the effect of metformin treatment 
A B
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P
P
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Figure 1
Dose response to metformin (0–10 mM) in PCa 
cell lines. Graphs show changes in % cell death 
in response to metformin. (A) DU145 cells were 
exposed to metformin in different glucose 
concentrations (5–25 mM). Cells were plated in 
six-well dishes (0.2 × 106 cells/well or 0.3 × 106 for 
LNCaP cells) in 5 mM glucose GM. The next day, 
media was switched to SFM containing different 
glucose concentrations (5 mM or 25 mM) for 
another 24 h. Cells were then dosed with 
metformin for a further 24 h. Dead cells were 
counted using trypan blue cell staining. 
(B) LNCaP, (C) PC3 and (D) VCaP cells were set up 
as described in Fig. 1A and levels of cell death 
were assessed using trypan blue staining. 
Graphs show mean of three experiments each 
repeated in triplicate.
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in addition to Docetaxel. With DU145, we confirmed 
that hyperglycaemia conferred survival in response to 
Docetaxel: 4.2% (2.8-fold) increase in cell death in 5 mM 
vs 1.8% (1.8-fold) increase in 25 mM glucose conditions 
and to metformin alone: 5.9% (3.6-fold) in normal 
glucose in comparison to 1.9% (1.8-fold) increase in 
high glucose, but in combination, high glucose could 
no longer confer a protective effect against Docetaxel, 
and there was a synergistic increase in cell death in both 
levels of glucose. Docetaxel plus metformin treatment 
was effective in both glucose conditions and induced a 
15.7% (7.6-fold) and 14.4% (7.3-fold) increase in cell 
death in 5 and 25 mM glucose respectively (Fig.  3A). A 
similar pattern was observed with LNCaP cells (Fig.  3B) 
where Docetaxel elevated the levels of dead cells by 20% 
(2.8-fold) in 5 mM glucose and only by 3.7% (1.3-fold) 
in 25 mM glucose and metformin alone induced a 38% 
(4.5-fold) increase in cell death in normal glucose 
compared with 11% (1.3-fold) in high glucose, whereas 
both drugs resulted in an additive effect of 44% (5-fold) 
and 37% (3.9-fold) elevated level of dead cells in 5 mM 
and 25 mM glucose conditions respectively. As described 
previously, there was no difference in response of PC3 
and VCaP cells to a single treatment with Docetaxel or 
metformin with either normal or high levels of glucose. The 
combination treatment as anticipated did not induce any 
additional effect in relation to cell death (Fig. 3C and  D).
Having observed the beneficial effect of metformin on 
chemotherapy-induced cell death negating the effect of 
high glucose, we investigated the mechanism underlying 
these responses. It has previously been reported that 
metformin downregulates the levels of IGF-IR in prostate 
Figure 2
Changes in prostate cancer cell morphology treated with metformin (2.5–7.5 mM). (A) DU145 cells were plated in T-25 flasks (0.3 × 106 cells/flask) in 5 mM 
glucose GM. The next day, media was switched to SFM containing different glucose concentrations (5 mM or 25 mM) for additional 24 h. Cells were then 
dosed with metformin for a further 24 h. Metformin induced a dose-dependent reduction in cell number and increased cell detachment in 5 mM but not 
in 25 mM glucose conditions. (B) LNCaP cells were set up as described in Fig. 2A and metformin induced a dose-dependent reduction in cell number in 
5 mM but not in 25 mM glucose conditions. (C) VCaP cells were set up as described in Fig. 2A and metformin treatment induced some reduction in cell 
number in 5 mM but not in 25 mM glucose conditions. (D) PC3 cells were set up as described in Fig. 2A. Metformin did not alter cell number in either 
5 mM or in 25 mM glucose conditions. All images were acquired under 10× magnification.
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cancer cells (Malaguarnera et al. 2014, Kato et al. 2015), 
but we assessed the abundance of IGF-IR by Western 
blotting and measured the levels of IGF-I and IGF-II by 
radioimmunoassay, and none of these variables were 
altered in the DU145 or LNCaP cells in these experiments 
(data not shown). Metformin activates AMPK, a central 
energy sensor of the cell, and this can be mediated by a 
separate kinase LKB1 (Zakikhani et al. 2006). We screened 
DU145, LNCaP, PC3 and VCaP PCa cell lines for LKB1 
abundance in cell lysates. We could detect LKB1 protein in 
all cell lines except DU145 cells (Fig. 4A). Having identified 
the presence/absence of LKB1, we investigated the 
impact of metformin on the phosphorylation of its direct 
target – AMPK (Fig. 4B). As anticipated, with DU145, we 
did not observe the activation of AMPK in the presence 
of metformin due to the lack of LKB1. Interestingly, there 
was even a decrease in P-AMPK (Fig. 4B) in 5 mM glucose 
compared with no effect in 25 mM glucose conditions. 
We then examined PC3, LNCaP and VCaP cells, which 
are LKB1 positive and found that metformin could dose 
dependently activate AMPK in each of these cell lines in 
both glucose conditions (Fig. 4C, D and E respectively).
We previously published that the protective effect of 
hyperglycaemia in response to Docetaxel was mediated 
by IGFBP-2 (Biernacka et  al. 2013). As we had observed 
a similar protective effect of high glucose against 
A B
C D
D
D
D
D D
P
P
P
P
Figure 3
Changes in % cell death in response to single or 
combination treatment with Docetaxel 
(35–60 nM) and metformin (5 mM) in prostate 
cancer cell lines. (A) DU145 cells were set up as 
described in Fig. 1A and dosed with 35 nM 
Docetaxel, 5 mM metformin or with both for a 
further 24 h. (B) LNCaP cells were set up as 
described in Fig. 1A and dosed with 60 nM 
Docetaxel, 5 mM metformin or combined 
treatment for a further 24 h. (C) PC3 cells were set 
up as described in Fig. 1A and dosed with 45 nM 
Docetaxel, 5 mM metformin or both for a further 
24 h. (D) VCaP cells were set up as described in 
Fig. 1A and treated with 45 nM Docetaxel, 5 mM 
metformin or both for another 24 h. For all 
figures, levels of % cell death were assessed using 
trypan blue cell counting. All graphs show mean 
of three experiments each repeated in triplicate.
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metformin-induced cell death in DU145 and LNCaP cells, 
we then examined the influence of metformin on IGFBP-
2. With both DU145 and LNCaP PCa cell lines, metformin 
was able to decrease mRNA levels of the IGFBP-2 gene 
(Fig.  5A respectively). This decrease in gene expression 
resulted in a dose-dependent decrease in IGFBP-2 protein 
from whole cell lysates (Fig. 5B) as well as secreted into 
the conditioned media (Fig.  5C). The densitometry 
graphs show a statistically significant reduction in 
IGFBP-2 adjusted to loading control with a set dose of 
metformin (5 mM) compared with control in either 
euglycaemic or hyperglycaemic conditions (Fig. 5B and  C 
inserts). As previously stated, in PC3 and VCaP cells, we 
did not observe any additional benefit of metformin in 
combination with chemotherapy. Levels of IGFBP-2 in 
PC3 cells are almost undetectable (Fig. 5D) and therefore 
we used VCaP cells as a negative control in investigating 
the associations between IGFBP-2 and metformin. 
A D
B
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Figure 4
(A) DU145, PC3, LNCaP and VCaP PCa cell lines were screened for abundance of LKB1 protein. Cells were grown in growth media and whole-cell lysates 
were prepared and subjected to Western blotting. (B) Changes in p-AMPK levels after metformin (2.5–7.5 mM) treatment. DU145 cells were seeded in 
5 mM glucose for 24 h, which was replaced with either 5 mM or 25 mM SFM for a further 24 h. Cells were then treated with metformin (2.5–7.5 mM) for 
24 h and whole-cell lysates were prepared and subjected to Western blotting. 50 µg of protein were loaded onto a 10% gel. (C) Shows levels of p-AMPK 
in PC3 cells exposed to metformin (2.5–7.5 mM) treatment. Cells were set up as described in Fig. 4B. (D) Shows levels of P-AMPK in LNCaP cells exposed to 
metformin (2.5 and 5 mM) treatment. Cells were set up as described in Fig. 4B. (E) Shows levels of p-AMPK in VCaP cells exposed to metformin (5 and 
7.5 mM) treatment. Each blot is representative of experiments repeated three times, and the densitometry shows the changes of p-AMPK adjusted to 
loading control for all experiments (n = 3).
24Research K M Biernacka et al. Effects of metformin  
on chemotherapy
En
d
o
cr
in
e-
R
el
at
ed
 C
an
ce
r
DOI: 10.1530/ERC-16-0095
http://erc.endocrinology-journals.org © 2017 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
24:1
We confirmed no change in mRNA level of the IGFBP-2 
gene in either 5 or 25 mM glucose conditions (Fig.  5E), 
no change in IGFBP-2 protein from whole cell lysates 
(Fig. 5F) or conditioned media (Fig. 5G). Having observed 
the beneficial effect of metformin in relation to elevated 
levels of cell death and its impact on IGFBP-2 protein and 
gene expression, we then assessed the effect of adding 
exogenous IGFBP-2, to counter the metformin-induced 
decrease, on metformin-induced cell death. Addition of 
exogenous IGFBP-2 significantly inhibited metformin 
(5 mM)-induced cell death of DU145 cells by 31.5% and 
20.7% with 5 and 7.5 mM metformin respectively (Fig. 6).
Having implicated IGFBP-2 in the effects of metformin 
on DU145 cells that lack LKB1, we then investigated the 
effect of metformin on LNCaP cells that unlike DU145 
cells express LKB1. With LNCaP cells, metformin had 
A D E
F
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P
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P P P P
P
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Figure 5
(A) Changes in mRNA levels of IGFBP-2 in response to 5 mM metformin treatment in either 5 mM or 25 mM glucose conditions. DU145 and LNCaP cells 
were seeded at 0.8 × 106 cells/T-25 flasks and cultured as described in Fig. 1A, mRNA was extracted 24 h after dosing with metformin and Q-PCR was 
performed. Values of IGFBP-2 gene expression were normalised to the housekeeping gene (18S) (n = 3). (B) Western immunoblots show changes in the 
abundance of IGFBP-2 from DU145 or LNCaP cell lysates respectively, exposed for 24 h to (1–10 mM) metformin in either 5 mM or 25 mM glucose. Cells 
were seeded at 0.5 × 106 cells/T-25 flask and cultured as described in Fig. 1A and whole-cell lysates were collected and subjected to Western blot 
technique. Each blot is representative of experiments repeated three times, and the densitometry shows the mean changes (n = 3). (C) Western 
immunoblot shows changes in the abundance of IGFBP-2 from DU145 cell supernatants exposed for 24 h to (1–10 mM) metformin in either 5 mM or 
25 mM glucose. Cells were set up as described in Fig. 1A, and conditioned media was collected and subjected to Western blot technique. Each blot is 
representative of experiments repeated three times and densitometry shows the mean changes at a representative dose of metformin (n = 3). 
(D) Western immunoblot shows changes in the abundance of IGFBP-2 in PC3 and VCaP cells. (E) Changes in mRNA levels of IGFBP-2 in response to 5 mM 
metformin treatment in either 5 mM or 25 mM glucose conditions. VCaP cells were seeded at 0.8 × 106 cells/T-25 flasks and cultured as described in 
Fig. 1A, mRNA was extracted 24 h after dosing with metformin and Q-PCR was performed. Values of IGFBP-2 gene expression were normalised to the 
housekeeping gene (18S) (n = 3). (F) Western immunoblots show changes in the abundance of IGFBP-2 from VCaP cell lysates respectively, exposed for 
24 h to (5–7.5 mM) metformin in either 5 mM or 25 mM glucose. (G) Western immunoblot shows changes in the abundance of IGFBP-2 from VCAP cell 
supernatants exposed for 24 h to (2.5–7.5 mM) metformin in either 5 mM or 25 mM glucose.
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the ability to phosphorylate AMPK (Fig.  4D) and was 
able to decrease IGFBP-2 gene and protein expression 
(Fig.  5). We then inhibited AMPK using Compound C 
(CC) but still observed a significant reduction in IGFBP-2 
gene expression in LNCaP cells treated with metformin 
in both glucose conditions (Fig.  7A) indicating that, as 
in the DU145 cells, the effect of metformin on IGFBP-2 
expression was independent of AMPK. Successful 
inhibition of phosphorylation of AMPK with CC was 
confirmed by Western immunoblotting (Fig. 7A, insert). 
Furthermore, silencing both catalytic subunits AMPK 
α1 and α2 with siRNA did not abrogate metformin-
induced inhibition of IGFBP-2 gene expression (Fig. 7B). 
Metformin could still reduce IGFBP-2 gene expression 
despite silencing AMPK suggesting an AMPK-independent 
mechanism of metformin action. Successful knockdown 
of AMPK was illustrated by Western immunoblot (Fig. 7B, 
insert). Consistent with this metformin could still reduce 
IGFBP-2 levels even in the presence of the AMPK inhibitor, 
Compound C (Supplementary Fig.  1A, see section on 
supplementary data given at the end of this article).
Having established that the impact of metformin 
on IGFBP-2 occurred independently of AMPK, we then 
examined whether the survival effect of high glucose 
was still present in LNCaP cells treated with Docetaxel, 
despite having silenced AMPK (Fig.  7C). With LNCaP, 
hyperglycaemia conferred resistance to Docetaxel in the 
presence of AMPK (12.4% difference between normal 
and high glucose level media) or with AMPK silenced 
(difference reduced to 6.4%, which was still significant).
In contrast, silencing IGFBP-2 negated high glucose-
mediated survival of LNCaP cells treated with Docetaxel 
or metformin alone. In high glucose conditions, when 
IGFBP-2 expression was enhanced neither Docetaxel nor 
metformin could induce cell death, but with IGFBP-2 
expression silenced, both could induce cell death, but 
there was no additive effect with the combination of 
metformin and Docetaxel (Fig. 7D).
Furthermore, the presence of the AMPK inhibitor, 
Compound C did not impact on the survival effect of 
high glucose in LNCaP cells treated with Docetaxel or 
metformin suggesting that AMPK is not a predominant 
pathway of metformin action (Supplementary Fig.  1B). 
Western blot shows that despite the small effect of CC 
in increasing the abundance of IGFBP-2, the opposite 
effect of metformin on IGFBP-2 protein was more robust 
(Supplementary Fig. 1A).
Discussion
During recent years, there has been an increasing amount 
of evidence suggesting that diabetes is associated with 
increased incidence and/or progression of cancer and 
correlates with poor prognosis and survival for patients 
suffering from pancreatic (Everhart & Wright 1995, Huxley 
et al. 2005), colon (Larsson et al. 2005), kidney (Larsson & 
Wolk 2011) or breast cancer (Larsson et al. 2007). Meta-
analysis of population-based studies, however, implied 
an opposite finding with prostate cancer, with diabetes 
acting as a protective factor against the risk of developing 
PCa (Kasper & Giovannucci 2006). A positive association 
between testosterone and prostate cancer was previously 
observed (Gann et  al. 1996). The fact that diabetes and 
insulin-resistance decreases the levels of testosterone may 
relate this a negative association of PCa and T2D (Meyer 
et al. 2010). Diabetes is often accompanied with co-morbid 
conditions like obesity. Observational studies confirmed 
that obesity contributes to an increased aggressiveness 
of prostate cancer (Rodriguez et al. 2007, Su et al. 2011, 
Capitanio et al. 2012).
These data clearly suggest a negative impact of 
impaired metabolic status on prostate cancer progression. 
Our previous study evaluated the effects of elevated 
glucose levels on the ability of prostate cancer cell lines to 
respond to chemotherapy. Hyperglycaemia inhibited the 
efficacy of Docetaxel in inducing apoptosis of DU145 and 
LNCaP but not PC3 cell lines (Biernacka et al. 2013).
A common drug used to improve insulin resistance-
associated glycaemic disturbances is metformin. This study 
investigated the effect of metformin on chemotherapy-
induced cell death of prostate cancer cell lines and suggests 
a novel underlying mechanism. With DU145 and LNCaP 
DU145
P
P
P
Figure 6
Changes in % cell death in response to treatment of metformin and/or 
IGFBP-2. DU145 cells seeded in six-well plates at 0.2 × 106 cell/well with 
5 mM glucose for 24 h. Cells were then transferred to 5 mM SFM and were 
treated for 24 h with 250 mM IGFBP-2 and/or 2.5–7.5 mM metformin. 
Cell death was assessed using trypan blue cell counting. Graph shows the 
mean of four experiments each repeated in triplicate.
26Research K M Biernacka et al. Effects of metformin  
on chemotherapy
En
d
o
cr
in
e-
R
el
at
ed
 C
an
ce
r
DOI: 10.1530/ERC-16-0095
http://erc.endocrinology-journals.org © 2017 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
24:1
PCa cells, we observed increased cell death in response to 
metformin alone in euglycaemic conditions, and the effect 
was reduced in hyperglycaemic conditions. In contrast, 
metformin has less of an effect on PC3 or VCaP cells, and 
hyperglycaemia was also without effect on the response 
of these cells. These data are consistent with other in vitro 
studies where metformin dose dependently (1 mM and 
5 mM) decreased the ability LNCaP and DU145 cells to 
form colonies in soft agar (Ben Sahra et al. 2008). The same 
study indicated that LNCaP xenografts in diabetic mice 
treated with metformin had significantly reduced tumour 
growth (Ben Sahra et al. 2008). Colquhoun and coworkers 
used PC3 cells and with similar doses of metformin and 
found that metformin did not inhibit colony survival: 
these results are in keeping with our data showing that 
PC3 cells are much less sensitive to metformin treatment 
under euglycaemic and hyperglycaemic conditions 
(Colquhoun et al. 2012). Metformin absorption in human 
hepatocytes is facilitated by an organic cation transporter 1 
(OCT1) (Shu et  al. 2007). However, PC3 cells have 
abundant levels of OCT1 (Robles et al. 2002); therefore, 
this reduced sensitivity to metformin was clearly not 
LNCaP
LNCaP
LNCaP
LNCaP
A C
B D
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Figure 7
Changes in IGFBP-2 gene expression in response to different treatments in either 5 mM or 25 mM glucose conditions. (A) LNCaP cells were set up as 
described in Fig. 5A and pre-treated with an AMPK inhibitor – Compound C (2 µM) for 1 h before dosing with 5 mM metformin for another 24 h. 
The mRNA was extracted and Q-PCR was performed. Values of IGFBP-2 gene expression were normalised to the housekeeping gene (18S) (n = 3). Western 
blot insert shows successful inhibition of metformin-induced AMPK phosphorylation by Compound C. (B) LNCaP cells were transfected with 75 nM siRNA 
for α1 and α2 subunits of AMPK or 25 mM non-silencing control, whereas seeding in six-well plates (0.3 × 106 cells/well) with 5 mM glucose and cultured as 
described in Fig. 1A. After 24 h treatment with 5 mM metformin, mRNA was extracted and Q-PCR was performed. Values of IGFBP-2 gene expression 
were normalised to the house-keeping gene (18S) (n = 3). (C) Changes in % cell death of LNCaP cells silenced with 75 nM siRNA for AMPK or 25 nM 
non-silencing control, whereas seeding in six-well plates (0.3 × 106 cells/well) with 5 mM glucose and cultured as described in Fig. 1A. After 24 h treatment 
with 60 nM Docetaxel for further 24 h, levels of cell death were assessed using trypan blue cell counting (n = 3). Western blot insert shows effective 
silencing of AMPK. (D) Changes in % cell death of LNCaP cells set up as described in Fig. 6C but silenced with 30 nM IGFBP-2 siRNA or 25 nM non-
silencing control and treated with 5 mM metformin or/and with 60 nM Docetaxel for 24 h. Cell death was assessed by counting using trypan blue (n = 3). 
Western blot insert shows effective silencing of IGFBP-2.
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limited by the uptake of metformin into PC3 cells. On 
examining the impact of metformin on the response of 
PCa cells to chemotherapy, we found that with DU145 
cells, the hyperglycaemia-induced reduction in response 
to Docetaxel or metformin alone were abolished in the 
presence of both drugs and a similar pattern was observed 
in LNCaP cells. Interestingly, the combined treatment 
also stimulated an increase in cell death in both 5 mM and 
25 mM glucose conditions. This suggests a beneficial effect 
of metformin usage for patients with normal or disturbed 
metabolic conditions such as diabetes. Epidemiological 
data indicate that prostate cancer patients who also suffer 
from diabetes have better outcomes when their diabetes 
is being treated with metformin (Wright & Stanford 2009, 
Morden et  al. 2011). This indicates that Docetaxel and 
metformin together could markedly benefit PCa patients 
with or without co-existing diabetes. Interestingly, a study 
of 1734 men after radical prostatectomy or radiotherapy 
for localised PCa showed that out of ‘ever’ metformin users 
(n = 366), 143 (21%) patients taking metformin before 
and after diagnosis had decreased risk of prostate cancer 
biochemical recurrence (HR 0.55, 95% CI 0.31–0.96). In 
addition, when examining prostate needle biopsies from 
a subgroup, the use of metformin was associated with 
higher cytoplasmic staining of IGF-1R in men with PCa 
(Winters et al. 2015). This suggested that use of metformin 
could modify the IGF signalling pathways and potentially 
influence the development of PCa.
There is an increasing interest in understanding how 
metformin exerts its antineoplastic activity. It was most 
commonly thought that metformin acted via activation 
of AMPK, which is a central energy-sensing system of 
the cell, and that it did this via a separate kinase, LKB1 
(Zhuang & Miskimins 2008). Once activated, AMPK 
inactivates a number of anabolic enzymes (such as fatty 
acid synthase; FASN) involved in ATP-consuming events 
such as fatty acid and protein synthesis and activates 
ATP-generating pathways like fatty acid oxidation (Foretz 
et al. 1998, Algire et al. 2010). Activated AMPK can control 
cell growth and proliferation by inhibiting mammalian 
target of rapamycin (mTOR) activity (Wullschleger et al. 
2006). This results in an inhibition of proteins synthesis 
and proliferation.
We investigated the mechanism underlying the 
ability of metformin to induce cell death of prostate 
cancer cells. When screening PCa cell lines for LKB1 
protein abundance, we found that among DU145, PC3, 
LNCaP and VCaP cells, only DU145 cells were LKB1 
negative. We then examined the impact of metformin 
on AMPK activation. As anticipated, with DU145 we 
did not observe an increased phosphorylation of AMPK, 
which is in keeping with an involvement of LKB1 in 
AMPK activation. However, with LNCaP cells, there was 
a metformin-induced AMPK activation at threonine 172, 
which is thought to be phosphorylated by LKB1. Our 
findings show that metformin could induce cell death in 
both DU145 and LNCaP cells, suggesting that metformin 
can act in a LKB1–AMPK-independent way to induce cell 
death. This is not in agreement with studies that imply 
that LKB1 is essential for metformin-induced cell growth 
inhibition. Cell growth was not inhibited in LKB1-
negative HeLa cells or MDA-MB-231 breast cancer cells in 
contrast to the inhibition observed with MC7, MCF10a 
and PC3 prostate cancer cells (Zakikhani et  al. 2006). 
Others, however, have reported that metformin was able 
to reduce tumour growth mediated by high-fat diet and 
high glucose regardless of LKB1 expression in vivo (Algire 
et  al. 2011). In addition, specific silencing of the AMPK 
pathway using siRNA to both catalytic subunits of AMPKα 
did not prevent the antiproliferative effect of metformin 
on PCa cell lines as well as reduce tumour growth in vivo 
in mouse LNCaP xenografts (Ben Sahra et  al. 2008). 
These findings are in keeping with our results and show 
that LKB1 and activation of AMPK are not necessary for 
metformin to exert its anti-tumourigenic activity.
Our previous paper showed that the survival effect 
of hyperglycaemia was mediated by increased IGFBP-2 
that can act in both, an IGF-IR-dependent manner in PC3 
cells and intrinsically (independent of IGF interaction) 
in DU145 and LNCaP cells (Uzoh et  al. 2011). IGFBP-2 
is an established mitogen and survival factor for PCa 
(Chatterjee et al. 2004, Uzoh et al. 2011). Based on these 
findings, we have investigated a role of IGFBP-2 in relation 
to metformin actions. Metformin induced a decrease in 
IGFBP-2 mRNA levels in DU145 and LNCaP, but not in 
VCaP cells. This was observed in both 5 mM and 25 mM 
glucose concentrations. The metformin-induced decrease 
in IGFBP-2 gene expression in DU145 and LNCaP cells was 
accompanied with a reduction of IGFBP-2 protein from 
cell lysates as well as IGFBP-2 secreted into the media. 
There was no effect of metformin on IGFBP-2 protein 
and mRNA expression in VCaP cells. The pro-apoptotic 
effect of metformin was diminished when the reduced 
expression of IGFBP-2 was replaced by the addition of 
exogenous IGFBP-2 in DU145 cells. Bearing in mind that 
DU145 cells do not express the LKB1 protein and that 
AMPK was not activated with metformin, we suggest 
that the LKB1-AMPK-independent action of metformin 
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was, at least in part, via downregulation of the survival 
factor IGFBP-2. We published previously that high glucose 
induced the upregulation of IGFBP-2 that was associated 
with an increase in the levels of acetylated histones H4 
and H3 associated with the IGFBP-2 gene in DU145 and 
LNCaP cells (Biernacka et  al. 2013). Our study indicates 
that metformin downregulates IGFBP-2 to negate the 
chemoresistance induced by high glucose: it will be 
interesting to determine if epigenetic modification of 
IGFBP-2 is a mechanism by which metformin is able to 
regulate IGFBP-2 levels.
In addition to the ability of metformin to 
phosphorylate AMPK in LKB1-positive LNCaP cells, we 
have also observed that metformin was also able to reduce 
gene and protein expression of IGFBP-2. Investigation at 
the mRNA level of IGFBP-2 showed that metformin was 
still able to downregulate IGFBP-2 gene after silencing 
AMPK using siRNA or inhibiting AMPK with Compound 
C. In addition, silencing AMPK did not alter the protective 
effect of high glucose in reducing Docetaxel-mediated 
cell death, suggesting that inhibition of AMPK did not 
influence the ability of IGFBP-2 to act as a survival factor 
in LNCaP cells. Furthermore, after knockdown of IGFBP-2, 
exposure to 25 mM glucose was no longer protective 
against Docetaxel or metformin treatment in relation to 
apoptosis suggesting that these protective effects were 
mediated by IGFBP-2. In addition to that, metformin was 
also able to exert its action in high and low glucose media 
even in the presence of Compound C again indicating 
this effect was not dependent on the activation of AMPK.
These findings suggest that metformin could induce 
cell death independently of the presence of LKB1 and 
without the involvement of AMPK but facilitated by 
the reduction of IGFBP-2 (a survival factor for PCa 
cells). This suggests that a novel potential mechanism 
of the anti-cancer effects of metformin may be by the 
regulation of IGFBP-2.
As members of the kinesin family have previously 
been shown to play a role in mediating taxane resistance 
in prostate cancer (Tan et  al. 2012), we investigated if 
the kinesins most implicated in prostate cancer (Eg5 and 
KIF3a) were involved in our model of hyperglycaemia-
induced chemoresistance. Our preliminary investigations 
did not provide any evidence that either Eg5 or KIF3a 
played a role; however, further work would be required to 
definitively eliminate the possible involvement of these 
and other members of this large family of kinesins.
Recently, there has been debate as to how data 
from in vitro studies of metformin translate into 
in  vivo activity in animal models and clinical trials, 
as the majority of work in vitro has been performed 
using concentrations varying from 1 to 100 mM, 
predominantly between 1 and 20 mM (Dowling et  al. 
2007, Ben Sahra et  al. 2008, Zakikhani et  al. 2008, 
Hwang & Jeong 2010, Colquhoun et al. 2012, Lau et al. 
2014). Such concentrations exceed levels measured in 
the blood of diabetic patients (Frid et al. 2010), although 
many organs like liver, kidney or small intestine are 
exposed to much higher concentration of metformin 
compared with levels measured in blood (Owen et al. 
2000). Importantly, plasma membrane monoamine 
transporter (PMAT) or equilibrative nucleoside 
transporter ENT-4 facilitates metformin absorption 
from the lumen (Zhou et al. 2007). Other studies show 
the importance in expression of the OCT family to 
build up intracellular levels of metformin (Wilcock & 
Bailey 1994, Shu et al. 2007), and blocking OCT-1, -2 
and -3 inhibited OCT-mediated transport of metformin 
(Nies et al. 2011). There is little evidence for the actual 
physiological concentrations of metformin achieved 
in normal and prostate cancer tissues although clearly 
metformin could accumulate over time.
The effect of metformin alone on the induction of 
cell death was much greater in normal glucose conditions 
and diminished in hyperglycaemia, but co-treatment 
with metformin and Docetaxel resulted in synergistic or 
additive effects and negated the hyperglycaemia-mediated 
reduction in sensitivity to Docetaxel. Investigating 
potential mechanisms through which metformin can 
act, we found that the presence of LKB1 and activation 
of AMPK were not required. In cells where metformin 
acted and potentiated the response to Docetaxel, this was 
associated with a reduction in the expression of IGFBP-2 
and a loss of its prosurvival actions.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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